RANI THERAPEUTICS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.65 USD | -0.30% |
|
-3.20% | +100.30% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 175M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M | Net income 2025 * | -32M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 119K | Net Debt 2025 * | 50M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.94
x | P/E ratio 2025 * |
-9.2
x | Employees | 140 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on Rani Therapeutics Holdings, Inc.
More recommendations
More press releases
| 1 day | -0.30% | ||
| 1 week | -3.20% | ||
| Current month | +113.83% | ||
| 1 month | +105.56% | ||
| 3 months | +81.20% | ||
| 6 months | +239.29% | ||
| Current year | +100.30% |
1 week
5.50
8.75
1 month
2.858.75
Current year
2.828.75
1 year
1.828.75
3 years
1.8236.27
5 years
1.8236.27
10 years
1.8236.27
| Managers | Title | Age | Since |
|---|---|---|---|
Talat Imran
CEO | Chief Executive Officer | 43 | 21-05-31 |
Mir Imran
FOU | Founder | 68 | 21-04-05 |
Svai Sanford
DFI | Director of Finance/CFO | 53 | 21-04-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Laureen DeBuono
BRD | Director/Board Member | 66 | 21-04-05 |
Jean-Luc Butel
BRD | Director/Board Member | 67 | 21-04-05 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-04-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 6.69 | +0.30% | 92,585 |
| 24-04-22 | 6.67 | -5.66% | 194,736 |
| 24-04-19 | 7.07 | +16.86% | 208,579 |
| 24-04-18 | 6.05 | -22.93% | 586,977 |
| 24-04-17 | 7.85 | +14.26% | 1,403,877 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.67
USD
Average target price
8.857
USD
Spread / Average Target
+32.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +100.30% | 175M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- RANI Stock
